Biosyent Short Long Term Debt Total vs Accounts Payable Analysis

RX Stock  CAD 11.52  0.18  1.54%   
Biosyent financial indicator trend analysis is way more than just evaluating Biosyent prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biosyent is a good investment. Please check the relationship between Biosyent Short Long Term Debt Total and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Biosyent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Short Long Term Debt Total vs Accounts Payable

Short Long Term Debt Total vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biosyent Short Long Term Debt Total account and Accounts Payable. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Biosyent's Short Long Term Debt Total and Accounts Payable is -0.09. Overlapping area represents the amount of variation of Short Long Term Debt Total that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Biosyent, assuming nothing else is changed. The correlation between historical values of Biosyent's Short Long Term Debt Total and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt Total of Biosyent are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Short Long Term Debt Total i.e., Biosyent's Short Long Term Debt Total and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.09
Relationship DirectionNegative 
Relationship StrengthInsignificant

Short Long Term Debt Total

Accounts Payable

An accounting item on the balance sheet that represents Biosyent obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Biosyent are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Biosyent's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biosyent current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Biosyent. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
At this time, Biosyent's Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 11.61 in 2024, whereas Selling General Administrative is likely to drop slightly above 6 M in 2024.
 2021 2022 2023 2024 (projected)
Total Revenue28.6M27.9M31.6M33.2M
Depreciation And Amortization457.1K451.0K455.3K478.1K

Biosyent fundamental ratios Correlations

-0.04-0.240.961.00.78-0.51.00.960.570.930.150.990.150.830.59-0.140.961.00.250.650.40.960.86-0.640.61
-0.040.41-0.1-0.03-0.08-0.41-0.09-0.090.37-0.190.130.020.94-0.260.07-0.5-0.1-0.02-0.950.140.33-0.07-0.270.450.12
-0.240.41-0.11-0.26-0.220.08-0.28-0.15-0.11-0.32-0.16-0.230.36-0.14-0.210.0-0.15-0.23-0.42-0.260.17-0.32-0.220.2-0.21
0.96-0.1-0.110.940.78-0.390.950.990.460.90.020.930.090.890.48-0.120.990.960.320.510.480.910.87-0.750.47
1.0-0.03-0.260.940.76-0.521.00.950.580.930.150.990.160.820.59-0.140.941.00.230.680.370.960.85-0.620.65
0.78-0.08-0.220.780.76-0.430.770.740.530.780.450.78-0.030.60.8-0.010.870.780.230.290.540.680.62-0.60.1
-0.5-0.410.08-0.39-0.52-0.43-0.49-0.32-0.99-0.31-0.2-0.61-0.380.02-0.560.42-0.41-0.520.37-0.66-0.61-0.350.0-0.16-0.48
1.0-0.09-0.280.951.00.77-0.490.960.560.930.130.990.110.830.59-0.110.951.00.290.660.360.960.87-0.650.63
0.96-0.09-0.150.990.950.74-0.320.960.40.910.020.930.120.920.44-0.070.970.960.320.520.370.950.92-0.760.52
0.570.37-0.110.460.580.53-0.990.560.40.390.240.680.340.060.63-0.390.50.59-0.310.650.650.420.080.070.46
0.93-0.19-0.320.90.930.78-0.310.930.910.390.240.880.020.880.55-0.020.920.910.370.540.320.880.87-0.670.52
0.150.13-0.160.020.150.45-0.20.130.020.240.240.160.07-0.040.72-0.090.130.13-0.180.18-0.120.040.010.250.06
0.990.02-0.230.930.990.78-0.610.990.930.680.880.160.180.740.64-0.180.940.990.170.70.450.930.79-0.570.64
0.150.940.360.090.16-0.03-0.380.110.120.340.020.070.180.00.04-0.580.060.16-0.870.230.270.15-0.040.290.27
0.83-0.26-0.140.890.820.60.020.830.920.060.88-0.040.740.00.260.030.860.820.470.320.140.870.95-0.840.38
0.590.07-0.210.480.590.8-0.560.590.440.630.550.720.640.040.26-0.140.590.590.020.350.290.450.35-0.20.22
-0.14-0.50.0-0.12-0.14-0.010.42-0.11-0.07-0.39-0.02-0.09-0.18-0.580.03-0.14-0.09-0.150.46-0.3-0.17-0.10.1-0.26-0.22
0.96-0.1-0.150.990.940.87-0.410.950.970.50.920.130.940.060.860.59-0.090.960.310.480.510.890.85-0.740.41
1.0-0.02-0.230.961.00.78-0.521.00.960.590.910.130.990.160.820.59-0.150.960.230.660.410.960.85-0.630.62
0.25-0.95-0.420.320.230.230.370.290.32-0.310.37-0.180.17-0.870.470.020.460.310.23-0.05-0.230.30.49-0.66-0.02
0.650.14-0.260.510.680.29-0.660.660.520.650.540.180.70.230.320.35-0.30.480.66-0.050.170.620.390.020.91
0.40.330.170.480.370.54-0.610.360.370.650.32-0.120.450.270.140.29-0.170.510.41-0.230.170.230.08-0.22-0.01
0.96-0.07-0.320.910.960.68-0.350.960.950.420.880.040.930.150.870.45-0.10.890.960.30.620.230.91-0.70.61
0.86-0.27-0.220.870.850.620.00.870.920.080.870.010.79-0.040.950.350.10.850.850.490.390.080.91-0.830.47
-0.640.450.2-0.75-0.62-0.6-0.16-0.65-0.760.07-0.670.25-0.570.29-0.84-0.2-0.26-0.74-0.63-0.660.02-0.22-0.7-0.83-0.01
0.610.12-0.210.470.650.1-0.480.630.520.460.520.060.640.270.380.22-0.220.410.62-0.020.91-0.010.610.47-0.01
Click cells to compare fundamentals

Biosyent Account Relationship Matchups

Biosyent fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets31.0M33.6M37.2M40.5M41.5M43.6M
Other Current Liab198.8K328.8K98.7K318.0K138.4K228.7K
Total Current Liabilities3.4M5.1M4.1M5.7M5.5M5.8M
Total Stockholder Equity25.8M26.8M31.6M33.4M34.8M36.5M
Property Plant And Equipment Net2.5M2.2M1.9M1.7M1.4M1.5M
Net Debt(11.6M)(18.6M)(16.5M)(6.5M)(3.7M)(3.9M)
Retained Earnings17.5M19.1M24.1M25.9M27.5M28.9M
Accounts Payable2.9M3.7M3.6M5.1M5.1M5.3M
Cash13.4M20.3M18.0M7.9M4.9M5.4M
Non Current Assets Total4.1M3.8M3.1M3.3M5.7M5.9M
Cash And Short Term Investments22.0M25.6M28.2M28.7M26.2M27.5M
Common Stock Shares Outstanding13.9M13.1M12.9M12.5M12.2M13.5M
Liabilities And Stockholders Equity31.0M33.6M37.2M40.5M41.5M43.6M
Inventory2.1M2.1M2.2M4.5M5.9M6.2M
Other Current Assets648.8K307.6K456.0K255.0K243.5K163.3K
Other Stockholder Equity1.2M1.5M1.8M2.2M2.3M3.1M
Total Liab5.2M6.8M5.6M7.1M6.8M7.1M
Total Current Assets26.8M29.8M34.1M37.1M35.9M37.7M
Intangible Assets1.0M1.0M874.0K1.2M1.2M660.8K
Current Deferred Revenue99.1K934.4K313.6K164.4K134.5K138.0K
Net Receivables2.1M1.8M3.2M3.7M3.5M3.7M
Accumulated Other Comprehensive Income(105.3K)(166.7K)(185.3K)(143.1K)(177.5K)(168.6K)
Short Term Investments8.5M5.3M10.2M20.8M21.3M22.3M
Common Stock7.2M6.4M5.8M5.4M5.1M5.4M
Other Liab102.9K79.7K80.2K182.4K209.7K153.4K
Net Tangible Assets24.7M25.8M30.7M32.3M37.1M21.9M
Other Assets686.5K758.8K406.5K639.1K1.00.95
Non Current Liabilities Total1.8M1.6M1.5M1.4M1.2M851.1K
Property Plant Equipment2.4M2.1M1.8M1.6M1.9M961.5K
Deferred Long Term Liab72.0K131.0K124.1K170.6K196.2K98.8K
Net Invested Capital25.8M26.8M31.6M33.4M34.8M31.8M
Net Working Capital23.5M24.6M29.9M31.4M30.3M29.1M
Capital Stock7.2M6.4M5.8M5.4M5.1M5.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Biosyent Stock Analysis

When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.